ABT - Abbott Laboratories

NYSE - Nasdaq Real Time Price. Currency in USD
79.70
+0.07 (+0.09%)
As of 9:35AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close 79.63
Open 80.73
Bid 79.50 x 1800
Ask 80.42 x 800
Day's Range 79.64 - 79.90
52 Week Range 65.44 - 88.76
Volume 73,216
Avg. Volume 4,537,559
Market Cap 140.862B
Beta (3Y Monthly) 0.80
PE Ratio (TTM) 49.02
EPS (TTM) N/A
Earnings Date N/A
Forward Dividend & Yield 1.28 (1.61%)
Ex-Dividend Date 2019-07-12
1y Target Est N/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Abbott and Omada Health Partner to Offer Integrated Digital Health and Coaching Experience for People with Type 2 Diabetes
    PR Newswire

    Abbott and Omada Health Partner to Offer Integrated Digital Health and Coaching Experience for People with Type 2 Diabetes

    ABBOTT PARK, Ill. and SAN FRANCISCO, Oct. 14, 2019 /PRNewswire/ -- Abbott (ABT) and Omada Health announced today they are partnering to integrate Abbott's revolutionary FreeStyle Libre system, a continuous glucose monitoring (CGM) technology, with Omada Health's pioneering digital care program, aiming to create a new paradigm for people with Type 2 diabetes. More than 30 million Americans are living with diabetes – with roughly 95% of them living with Type 2 diabetes1 – and many are looking for simple ways to better manage their condition and overall health.

  • PR Newswire

    Late-Breaking Data Shows Abbott's MitraClip™ is Cost Effective, Increases Life Expectancy and Improves Quality of Life

    SAN FRANCISCO, Sept. 29, 2019 /PRNewswire/ -- Abbott (ABT) today announced new analyses of the landmark COAPTTM Trial that show the company's MitraClipTM device is cost effective and is projected to increase both life-expectancy and quality of life compared to guideline-directed medical therapy (GDMT) alone in heart failure patients with secondary mitral regurgitation (MR), or a leaky mitral heart valve.

  • PR Newswire

    New Data Demonstrate Strong Outcomes for Abbott Device to Repair Leaky Tricuspid Heart Valves

    SAN FRANCISCO, Sept. 28, 2019 /PRNewswire/ -- Abbott (ABT) today announced new data that suggest Abbott's investigational TriClip™ device may offer physicians an effective minimally invasive repair option for patients suffering from a leaky tricuspid valve, a condition also known as tricuspid regurgitation (TR). The tricuspid valve is located between the two chambers on the right side of the heart and is challenging to treat because of its location.

  • FDA Approves Abbott's "Low Dose," Recharge-Free Spinal Cord Stimulation System with up to Ten Year Battery Life* for People Living with Chronic Pain
    PR Newswire

    FDA Approves Abbott's "Low Dose," Recharge-Free Spinal Cord Stimulation System with up to Ten Year Battery Life* for People Living with Chronic Pain

    ABBOTT PARK, Ill., Sept. 26, 2019 /PRNewswire/ -- Abbott (ABT) today announced the U.S. Food and Drug Administration (FDA) has approved the company's Proclaim XR™ recharge-free neurostimulation system for people living with chronic pain. The Proclaim XR platform offers a low dose of Abbott's proprietary BurstDR™ stimulation waveform, which was created based on scientific insights from doctors and research to mimic natural patterns found in the brain.

  • PR Newswire

    U.S. FDA Clears Abbott's High Sensitivity Troponin-I Blood Test That Aids Doctors in Diagnosing Heart Attacks Faster and More Accurately

    ABBOTT PARK, Ill., Sept. 25, 2019 /PRNewswire/ -- Abbott (ABT) today announced that its ARCHITECT STAT High Sensitivity Troponin-I blood test has received clearance from the U.S. Food and Drug Administration (FDA). As one of the most researched troponin diagnostic tests, doctors in the U.S. can now utilize this proven technology to help detect heart attacks faster and more accurately than contemporary troponin tests.

  • PR Newswire

    Abbott Hosts Conference Call for Third-Quarter Earnings

    ABBOTT PARK, Ill., Sept. 18, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its third-quarter 2019 financial results on Wednesday, Oct. 16, 2019 , before the market opens.  The announcement will ...

  • PR Newswire

    Abbott Announces European Approval of Two Life-saving Heart Devices for Babies and Children

    The Masters HP™ 15mm rotatable mechanical heart valve and the Amplatzer Piccolo™ Occluder have received CE Mark and are now available in Europe and other countries that recognize CE Mark. Congenital heart defects (CHD) affect approximately 36,000 births in the European Union each year.i The Masters valve is the world's smallest mechanical heart valve and allows doctors to treat babies and toddlers in need of a mitral or aortic heart valve replacement.

  • PR Newswire

    Abbott Named the Industry Leader in Sustainability for the Seventh Consecutive Year on the Dow Jones Sustainability Index (DJSI)

    ABBOTT PARK, Ill., Sept. 16, 2019 /PRNewswire/ -- Abbott (ABT) has been named the Global Industry Leader in sustainability for the seventh consecutive year by the Dow Jones Sustainability Index (DJSI), one of the most prestigious global benchmarks for corporate sustainability. As the industry leader in Health Care Equipment & Supplies, the company earned top scores across all three key areas, including economic, social and environmental performance.

  • PR Newswire

    Abbott and Sanofi Partner to Integrate Glucose Sensing and Insulin Delivery Technologies to Help Change the Way Diabetes is Managed

    ABBOTT PARK, Ill. and PARIS, Sept. 16, 2019 /PRNewswire/ -- Abbott (ABT) and Sanofi are partnering to integrate glucose sensing and insulin delivery technologies that would help to further simplify how people with diabetes manage their condition. The two companies will take an innovative approach to connected care by developing tools that combine the revolutionary FreeStyle Libre technology with Sanofi′s insulin dosing information for future smart pens, insulin titration apps and cloud software. "As the global leader in continuous glucose monitoring, we see a significant opportunity to impact the health of millions of people living with diabetes by developing new tools and connectivity with Sanofi, a leader in the insulin space," said Jared Watkin, senior vice president, Diabetes Care, Abbott.

  • PR Newswire

    Abbott's Revolutionary FreeStyle® Libre System Now Reimbursed in the Two Largest Provinces in Canada

    ABBOTT PARK, Ill., Sept. 13, 2019 /PRNewswire/ -- Abbott (ABT), the global leader in sensor-based glucose monitoring, announced today that it has received public reimbursement in Ontario and Quebec for its FreeStyle® Libre system, becoming the first sensor-based glucose monitoring system to be listed by any provincial health plan in Canada. Quebec residents 18 years or older2 and Ontario residents using insulin are eligible for reimbursement under the public programs.  With its proven accuracy and ease of use,3 the FreeStyle Libre system replaces traditional blood glucose monitoring and allows patients to dose insulin based on the results.

  • PR Newswire

    Abbott Declares 383rd Consecutive Quarterly Dividend

    ABBOTT PARK, Ill., Sept. 12, 2019 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 32 cents per share. This marks the 383 rd consecutive quarterly ...

  • PR Newswire

    Abbott Announces New Data That Shows Artificial Intelligence Technology Can Help Doctors Better Determine Which Patients are Having a Heart Attack

    - New research found Abbott's algorithm created through machine learning could give doctors a more individualized calculation, leveraging factors such as age, sex and the changing dynamics of troponin ...

  • PR Newswire

    Ministry of Health of Rwanda, Society for Family Health Rwanda and Abbott Launch Pioneering Model of Primary Health Care Service Delivery in Rwanda

    KIGALI, Rwanda, Sept. 9, 2019 /PRNewswire/ -- The Ministry of Health of Rwanda, the non-profit organization Society for Family Health Rwanda and global healthcare company Abbott (ABT) are today announcing the grand opening of a second-generation health post in Gikundamvura Cell, Ruhuha Sector, Bugesera District. The new health post is part of a program to help bring accessible, affordable and enhanced quality health services to rural communities in Rwanda.

  • He's Back and He's Hydrated: Abbott and NFL Star Odell Beckham Jr. Partner for Pedialyte®
    PR Newswire

    He's Back and He's Hydrated: Abbott and NFL Star Odell Beckham Jr. Partner for Pedialyte®

    ABBOTT PARK, Ill., Sept. 6, 2019 /PRNewswire/ -- Abbott (ABT) announced today that it is teaming up with NFL star, Cleveland Browns wide receiver, and Pedialyte® fan, Odell Beckham Jr., to serve as a creative director and ambassador for Pedialyte. Known for more than 50 years as a go-to for rehydration, Pedialyte—which is found in the baby aisle—has, over the last few years, seen unprecedented use by consumers of all ages, including athletes, who rely on it for advanced rehydration.

  • PR Newswire

    New Study Finds Abbott's Blood Test Technology Could Help Detect Brain Injury Quickly, Even if CT Scan is Normal

    ABBOTT PARK, Ill., Aug. 26, 2019 /PRNewswire/ -- Abbott (ABT) announced that a new study, published in Lancet Neurology, found that elevated levels of a protein measured with the company's blood test under development could help detect mild traumatic brain injuries (TBIs), even when a CT scan did not detect it.1  Findings from the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) study – one of the largest TBI efforts of its kind – show this new technology could help fill a gap in emergency rooms today by identifying patients who might otherwise have gone undiagnosed.

  • PR Newswire

    Together, We Can Increase the Number of Women in STEM: Here is a Tool to Help Companies Get Started

    Women who do pursue STEM degrees often don't take related jobs. Abbott (ABT) has found a promising way to help address these trends with our high school STEM internship program. This has inspired Abbott to today, Women's Equality Day, issue a call to action for other companies to join us – because it will take all of us to change the fact that less than a quarter of the STEM workforce is women.

  • PR Newswire

    Abbott and Intoximeters Partner to Keep Roads Safer by Bringing Together Industry-leading Technology for Drug and Alcohol Testing

    - Agreement gives law enforcement access to the most advanced handheld tools to help detect drug and alcohol-impaired drivers - Collaboration is a major step in keeping roads safer as recreational marijuana ...

  • PR Newswire

    Abbott Reports Second-Quarter 2019 Results

    - Accelerated and sustainable growth driven by strong performance across portfolio - Raising full-year guidance for organic sales growth to 7 to 8 percent - Double-digit EPS growth exceeded expectations; ...

  • ACCESSWIRE

    Abbott Laboratories to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July 17, 2019 / Abbott Laboratories (NYSE: ABT ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 17, 2019 at 9:00 AM Eastern ...

  • PR Newswire

    Abbott Receives U.S. Approval of Next-Generation MitraClip®, Bringing New Enhancements to Abbott's Leading MitraClip Platform

    ABBOTT PARK, Ill., July 15, 2019 /PRNewswire/ -- Abbott (ABT) today announced the company has received U.S. Food and Drug Administration (FDA) approval for the most advanced MitraClip™ heart valve repair device to treat mitral regurgitation. The latest approval for the fourth-generation MitraClip device, MitraClip G4, puts new enhancements into the hands of physicians across the U.S. by delivering an expanded range of clip sizes, an alternative leaflet grasping feature and facilitation of procedure assessment in real time to offer doctors further options when treating mitral valve disease.

  • PR Newswire

    Abbott Announces FDA Approval of the Alinity™ s System, the Latest Technology for Screening and Protecting the U.S. Blood and Plasma Supply

    ABBOTT PARK, Ill., July 11, 2019 /PRNewswire/ -- Abbott (ABT) announced today U.S. Food and Drug Administration (FDA) approval for its new blood and plasma screening Alinity™ s System.  This new solution will bring the latest screening technology to U.S. blood and plasma centers. Alinity s is designed to screen blood and plasma more efficiently within a smaller space versus commercially available competitive systems. In a testing specialty that can require extensive hands-on time, the additional automation and flexibility of Alinity s will help blood and plasma centers improve productivity and maintain the highest levels of accuracy. "Alinity s is a significant leap forward when it comes to speed, automation and efficiency for blood and plasma screening," said Louis Morrone, vice president, Transfusion Medicine, Abbott.

  • PR Newswire

    Nutrition Is the Missing Ingredient in Home Health Today, New Study Shows

    ABBOTT PARK, Ill., June 24, 2019 /PRNewswire/ -- New research from Advocate Health Care and Abbott (ABT) found that prioritizing nutrition care* for home health patients at risk for malnutrition had a dramatic impact on helping keep them out of the hospital - resulting in millions of dollars in healthcare cost savings. Nearly 5 million Americans annually rely on home healthcare to recover from an illness, injury or hospitalization.1,† While healthcare providers are constantly striving to improve patients' health and minimize hospitalizations, nutrition is often not top of mind, yet it plays a critical role in helping adults bounce back and resume their normal routine.

  • PR Newswire

    Abbott Hosts Conference Call for Second-Quarter Earnings

    ABBOTT PARK, Ill., June 19, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2019 financial results on Wednesday, July 17, 2019 , before the market opens.  The announcement will ...

  • PR Newswire

    CARE, Abbott and the Abbott Fund Launch Partnership to Address Noncommunicable Diseases (NCDs) in Humanitarian Settings

    ATLANTA and ABBOTT PARK, Ill., June 17, 2019 /PRNewswire/ -- The global humanitarian organization CARE, the healthcare company Abbott (ABT) and its foundation the Abbott Fund today announced a three-year, $1 million program to screen, diagnose, prevent and manage noncommunicable diseases (NCDs) for people who remain displaced two years after armed conflict in Marawi City, Philippines. The partnership is among the first of its kind to address NCDs in areas affected by disasters, conflict and other humanitarian challenges.